Navigation Links
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

is Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.

SOURCE Cordis Corporation

Mariela Melendez of Cordis Corporation, +1-786-313-2776, cell, +1-786-218-4084,
mmelen10@crdus.jnj.com; or Todd Ringler of Edelman, +1-617-872-1235,
todd.ringler@edelman.com
http://www.cordis.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX


'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
(Date:12/17/2014)...  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... (USPTO) has issued a key patent covering ImmunoCellular,s ... targeting six tumor antigens that are commonly expressed ... 8,871,211, which issued October 28, 2014, include methods ... cell composition comprising peptide epitopes of the six ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 2011 FDA Commissioner Margaret A. Hamburg, M.D., ... can be taken to drive biomedical innovation, while ... http://photos.prnewswire.com/prnh/20090824/FDALOGO) Titled "Driving Biomedical Innovation: Initiatives ... concerns about the sustainability of the medical product ...
... ConvaTec, a world-leading developer and marketer of innovative medical ... Ltd, a wholly-owned subsidiary of ConvaTec Holdings UK Ltd, has ... the home delivery of stoma and continence care products. ... of England, and as a well-respected company in the home ...
Cached Medicine Technology:FDA Commissioner Outlines Steps to Spur Biomedical Innovation, Improve Health of Americans 2ConvaTec Announces Acquisition of Farnhurst Medical 2
(Date:12/19/2014)... The Hermitage Club at Haystack Mountain, ... Deerfield Valley, announced today that it has unveiled its ... , Three time Grammy Award Winner Kenny Loggins ... by a trail naming ceremony. Hermitage Club Founder, President ... Alright” the theme song for the movie soundtrack to ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... at least 20 seconds you may be at risk of ... leg may indicate that small strokes or tiny bleeds have ... is high, the investigators reported online Dec. 18 in the ... on one leg, as well as problems walking, should receive ...
(Date:12/17/2014)... 17, 2014 This prestigious award ... that have made outstanding and innovative contributions to ... progression of private practice physical therapy by the ... Association. , On behalf of Performance Physical Therapy, ... CEO of Performance accepted the award at the ...
(Date:12/17/2014)... No matter how far modern medicine advances, it ... louse parasite—a common childhood malady and a source of ... and twelve million individuals will suffer an infestation. ... comes to the rescue, providing an all-natural treatment that ... record of customer service, and effectiveness in getting rid ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Dynamics Company,Ltd.) (TSX: IDL), the global leader in ... that it has been awarded a contract by,the ... India for,five X-Series 1600 DR systems with X4C ... placed for DR equipment by the government in,India ...
... not be the major cause of hyperactivity in children. Genetics, ... just as important. , A review ... actually affected by what they eat. A combination of food, ... with no single factor to blame. , Foods which ...
... Transplant,Foundation (MTF) will provide military hospitals with special ... for injured servicemen and,women., Military hospitals and ... for cartilage transplantation and meniscus grafts used for,joint ... tissue are in high,demand for U.S. servicemen and ...
... has awarded one of 14 Clinical and Translational Science ... Boston University Medical (BUMC) and Charles River Campuses and ... CTSAs awarded in 2007, and 12 awarded in 2006, ... a national consortium of select centers that will transform ...
... H. Antman, MD, provost of Boston University Medical Campus ... be honored with the Distinguished Service Award for Scientific ... at their annual meeting in Chicago this weekend. Antman, ... cancer, is widely recognized for her development of a ...
... a Useful Tool in Detection, as Sensitive as MRI ... Invasive Cancers and Perhaps More So for DCIS, NEWPORT ... June issue of Radiology, researchers at The George Washington,University Medical ... is highly sensitive in detecting the,presence of cancer. The researchers ...
Cached Medicine News:Health News:IDC awarded India's largest state government contract for digital radiography systems 2Health News:IDC awarded India's largest state government contract for digital radiography systems 3Health News:Children's diet not the main cause of ADHD 2Health News:BUMC, BMC receives Clinical and Translational Science Award from NIH 2Health News:BUMC provost, BUSM dean, to be honored at world's largest meeting of oncology professionals 2Health News:Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer 2
Porous foundation 470 series....
The Opteon stem meets the challenge of providing a high-quality, cost-effective hip implant for the moderate demand patient....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The link ribbed hip stem for cementless primary hip replacement surgery....
Medicine Products: